Cedric Francois - Mar 1, 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Cedric Francois
Stock symbol
APLS
Transactions as of
Mar 1, 2024
Transactions value $
-$14,978,706
Form type
4
Date filed
3/5/2024, 04:07 PM
Previous filing
Feb 13, 2024
Next filing
Nov 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $188K +50K +15.94% $3.76* 364K Mar 1, 2024 Direct F5
transaction APLS Common Stock Options Exercise $862K +200K +55% $4.31* 564K Mar 1, 2024 Direct F6
transaction APLS Common Stock Sale -$1.8M -28.9K -5.12% $62.21 535K Mar 1, 2024 Direct F7
transaction APLS Common Stock Sale -$2.63M -41.7K -7.8% $62.96 493K Mar 1, 2024 Direct F8
transaction APLS Common Stock Sale -$4.02M -62.5K -12.68% $64.26 431K Mar 1, 2024 Direct F9
transaction APLS Common Stock Sale -$7.56M -117K -27.06% $64.92 314K Mar 1, 2024 Direct F10
transaction APLS Common Stock Sale -$27.1K -413 -0.13% $65.68 314K Mar 1, 2024 Direct F11
holding APLS Common Stock 533K Mar 1, 2024 Indirect Owner (The Cedric Francois Irrevocable Trust of 2023 - 2) F1
holding APLS Common Stock 654K Mar 1, 2024 Indirect Owner (The Cedric Francois Irrevocable Trust of 2023) F2
holding APLS Common Stock 300K Mar 1, 2024 Indirect Owner (The Francois Grossi Trust) F3
holding APLS Common Stock 234K Mar 1, 2024 Indirect Owner (The Francois-DuBois Educational Trust) F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -50K -84.98% $0.00 8.84K Mar 1, 2024 Common Stock 50K $3.76 Direct F5, F12
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -200K -53.26% $0.00 176K Mar 1, 2024 Common Stock 200K $4.31 Direct F6, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The securities are held by The Cedric Francois Irrevocable Trust of 2023 - 2. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023 - 2. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 - 2 except to the extent of his pecuniary interest therein.
F2 The securities are held by The Cedric Francois Irrevocable Trust of 2023. William V. A. Zorn is the trustee of The Cedric Francois Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Cedric Francois Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
F3 The securities are held by The Francois Grossi Trust, for which Juliana Grossi, the spouse of the reporting person, serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Francois Grossi Trust except to the extent of his pecuniary interest therein.
F4 The securities are held by The Francois-DuBois Educational Trust, for which the Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by The Francois-DuBois Educational Trust except to the extent of his pecuniary interest therein.
F5 This is a scheduled exercise & sale from 10b5-1 trading plan dated 11/30/2023.
F6 This is a scheduled exercise & sale from 10b5-1 trading plan dated 11/30/2023.
F7 This transaction was executed in multiple trades at prices ranging from $61.615 - $62.605. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $62.61 - $63.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $63.665 - $64.645. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10 This transaction was executed in multiple trades at prices ranging from $64.6575 - $65.59 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 This transaction was executed in multiple trades at prices ranging from $65.67 - $65.69 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12 This option was granted on February 8, 2016 and fully vested.
F13 This option was granted on August 21, 2017 and is fully vested.